explore -WSS

explore

author：hotspot 2025-09-29 21:21:01 - browse：58

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Millions may soon lose Medicaid when they don't have to

hotspot

knowledge

WSS

Keeping primary care docs in field isn't impossible, says AAFP CEO

Medicare Advantage beneficiaries sue Humana over algorithm use

Biogen nominates mother of director’s child to replace him on board

Grail spinoff by Illumina should end disastrous merger attempt

Prime Medicine, Myeloid Therapeutics clash over genome

SNAP should offer more nutrition education

focus

explore

focus

Continuity nursing helped my family in our darkest PICU moments

Christmas in the PICU brings some surprising joy

In age of alternative facts, a scholarly course on calling out crap

Keeping primary care docs in field isn't impossible, says AAFP CEO

How one medical school became remarkably diverse

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Continuity nursing helped my family in our darkest PICU moments

CRISPR gene editing developments we’re watching in 2024

How one medical school became remarkably diverse

Senate panel passes drug pricing bills, but drops one PBM reform

explore

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Medicare drug price negotiation hasn't dried up venture capital

Xenotransplantation trials will require adjusting expectations, experts say

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Patients, doctors are clashing about side effects of hormonal birth control

Grail spinoff by Illumina should end disastrous merger attempt

hotspot

knowledge

hotspot

focus